within Pharmacolibrary.Drugs.ATC.J;

model J05AX09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.238,
    Cl             = 0.5950000000000001,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.194,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.017166666666666667,
    Tlag           = 10.319999999999999
  );

  annotation(Documentation(
    info ="<html><body><p>Maraviroc is an antiretroviral medication that acts as a CCR5 antagonist, used in combination therapy for the treatment of HIV-1 infection. It prevents viral entry into host cells by blocking the CCR5 co-receptor. Maraviroc is approved and currently in clinical use for HIV therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li>Julia C Rosebush, Brookie M Best, Ellen G Chadwick, Kevin Butler, John Moye, Elizabeth Smith, Sarah Bradford, Christina A Reding, Sisinyana R Mathiba, Sherika Hanley, Mariam Aziz, James Homans, Edward P Acosta, William Murtaugh, Manoli Vourvahis, Lynn Mcfadyen, Katy Hayward, Mark Mirochnick, Pearl Samson,Pharmacokinetics and safety of maraviroc in neonates.,AIDS (London, England),2021<a href='https://pubmed.ncbi.nlm.nih.gov/33252481/'>https://pubmed.ncbi.nlm.nih.gov/33252481/</a></li><li>Samantha Abel, David J Back, Manoli Vourvahis,Maraviroc: pharmacokinetics and drug interactions.,Antiviral therapy,2009<a href='https://pubmed.ncbi.nlm.nih.gov/19704163/'>https://pubmed.ncbi.nlm.nih.gov/19704163/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AX09;
